Erythropoietin: elucidating new cellular targets that broaden therapeutic strategies.
Given that erythropoietin (EPO) is no longer believed to have exclusive biological activity in the hematopoietic system, EPO is now considered to have applicability in a variety of nervous system disorders that can overlap with vascular disease, metabolic impairments, and immune system function. As a result, EPO may offer efficacy for a broad number of disorders that involve Alzheimer's disease, cardiac insufficiency, stroke, trauma, and diabetic complications. During a number of clinical conditions, EPO is robust and can prevent metabolic compromise, neuronal and vascular degeneration, and inflammatory cell activation. Yet, use of EPO is not without its considerations especially in light of frequent concerns that may compromise clinical care. Recent work has elucidated a number of novel cellular pathways governed by EPO that can open new avenues to avert deleterious effects of this agent and offer previously unrecognized perspectives for therapeutic strategies. Obtaining greater insight into the role of EPO in the nervous system and elucidating its unique cellular pathways may provide greater cellular viability not only in the nervous system but also throughout the body.
Maiese
Kenneth
K
Division of Cellular and Molecular Cerebral Ischemia, Wayne State University School of Medicine, Detroit, MI 48201, USA. aa2088@wayne.edu
Chong
Zhao Zhong
ZZ
Li
Faqi
F
Shang
Yan Chen
YC
D000818:Animals; D004921:Erythropoietin / Q000502:physiology* / Q000627:therapeutic use*; D006801:Humans; D009422:Nervous System Diseases / Q000188:drug therapy*
D004921:Erythropoietin